Rich Lin profile picture

Rich Lin – Acuta Capital Founder, CEO

Rich Lin, whose full name is Richard Lin, is the founder, CEO and managing member of Acuta Capital.

Prior to founding Acuta Capital, Rich Lin was a partner at Three Arch Partners, LP, a healthcare focused venture capital firm. Rich was a venture capitalist for over 13 years before founding Acuta and was an investor/board member of many healthcare companies in the therapeutics, medical device, healthcare services, and healthcare IT sectors. Rich’s previous investments include Calibra (acquired by J&J), Cameron (Boston Scientific), Confluent (Tyco), ePocrates (Athena Health), inGenuity (Qiagen), Inova (ResMed), Novacept (Cytyc), Salveo (Catamaran), Spiration (Olympus), Sirtris (GSK), Visiogen (Abbott), and Vivant (Tyco). Rich was a board member and seed investor in Calistoga (acquired by Gilead), which developed a Pi3k inhibitor that is now approved to treat NHL, CLL and Follicular Lymphoma. He also was one of the seed investors in Acerta Pharma B.V. (acquired by Astra Zeneca), which developed a BTK inhibitor that is now approved to treat Mantle Cell Lymphoma.

Rich Lin holds an M.D. from Harvard Medical School where he graduated cum laude and was also named a Howard Hughes Scholar for his research efforts at the National Institutes of Health. He has an M.B.A. from the Stanford Graduate School of Business where he was an Arjay Miller Scholar and he received his B.S., with honors and Phi Beta Kappa, from Stanford University. Rich was also a resident in surgery at the University of California, San Francisco, a member of the Therapeutic Advisory Council for Harvard Medical School, and on faculty at the Stanford Graduate School of Business.

With his impressive background as a physician, surgeon and scientist, Mr. Rich Lin not only understands the importance of innovation and the role it plays, but is incredibly passionate about how innovation impacts the medical field.

Photo ofRich Lin
Rich Lin
Job Title
founder, CEO and managing member of Acuta Capital
Acuta Capital